PLXS

Plexus Corp. 10-K Summary: Fiscal Year Ended September 30, 2003

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended September 30, 2003. Plexus Corp. provides product realization services, including design, manufacturing, and testing, to original equipment manufacturers (OEMs) in the networking/telecom, medical, industrial/commercial, computer, and transportation sectors. The company operates 19 active facilities across North America, Europe, and Asia. The reporting period was characterized by a significant contraction in the technology sector, leading to reduced sales, capacity utilization issues, and extensive restructuring efforts.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 9% to $807.8 million, driven by a slowdown in the networking/telecom and industrial/commercial markets and the loss of a primary customer program in San Diego.
• Margin Compression: Gross margin fell to 6.6% from 9.2% due to reduced capacity utilization, lower product pricing, and costs associated with transferring customer programs to other facilities.
• Restructuring and Impairment: The company recorded $59.3 million in pre-tax restructuring and impairment costs. This included closing facilities in San Diego and Richmond, consolidating leased facilities, and workforce reductions affecting approximately 1,000 employees.
• Accounting Changes: Adoption of SFAS No. 142 (Goodwill) resulted in a one-time transitional impairment charge of $28.2 million (pre-tax), recorded as a cumulative effect of a change in accounting.
• Cash Flow Reversal: Operating cash flow swung from a positive $130.5 million in 2002 to a negative $20.0 million in 2003, primarily due to funding losses, increased inventory, and the termination of an asset securitization facility.

Guidance, Outlook, and Risks

• Outlook: Management expects first-quarter fiscal 2004 sales to range between $230 million and $240 million, citing strengthened demand from existing customers and new program starts.
• Restructuring Savings: The company anticipates annualized cost savings of approximately $30 million from restructuring actions once fully implemented.
• Liquidity: On October 22, 2003, the company secured a new $100 million revolving credit facility to replace a terminated facility. Management believes current resources are sufficient to meet requirements through fiscal 2004.
• Key Risks:
  • High customer concentration: The top 10 customers accounted for 55% of sales; Siemens Medical Systems alone represented 12%.
  • Inventory risk: Turnkey manufacturing exposes the company to component price fluctuations and obsolescence.
  • ERP Implementation: Ongoing costs for a new enterprise resource planning system ($27.9 million capitalized as of Sept 2003) pose a risk if sales do not recover.
  • Legal: Ongoing litigation regarding patent infringement by the Lemelson Foundation, though management does not expect a material impact.

Investor Verification Checklist

• Customer Concentration: Verify the stability of the top 10 customers, particularly Siemens Medical Systems (12% of sales), given the risk of order cancellations.
• Restructuring Execution: Monitor the realization of the projected $30 million in annualized cost savings against actual operating expenses in upcoming quarters.
• Inventory Levels: Assess the $136.5 million inventory balance and the risk of write-downs given the 6.5x inventory turnover ratio and weak demand.
• Debt Covenants: Review compliance with the new $100 million credit facility covenants, specifically minimum adjusted EBITDA and tangible net worth requirements.
• ERP Costs: Track the $5.0 million+ in anticipated additional capital expenditures for the ERP platform and the potential for impairment if sales growth does not materialize.